> top > docs > PMC:3312845 > spans > 6715-8147 > annotations

PMC:3312845 / 6715-8147 JSONTXT

Annnotations TAB JSON ListView MergeView

2_test

Id Subject Object Predicate Lexical cue
22240205-21029730-63147413 1240-1241 21029730 denotes 5
22240205-2648633-63147413 1240-1241 2648633 denotes 5
22240205-21742016-63147413 1240-1241 21742016 denotes 5
22240205-20886625-63147413 1240-1241 20886625 denotes 5
22240205-20939924-63147414 1244-1246 20939924 denotes 20

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T3581 1425-1431 VB denotes peaked
T3580 1419-1424 NN denotes edema
T3579 1409-1418 JJ denotes vasogenic
T3578 1406-1408 IN denotes of
T3577 1399-1405 NN denotes volume
T3576 1395-1398 DT denotes the
T3575 1390-1394 WRB denotes when
T3574 1387-1389 NN denotes SE
T3573 1381-1386 IN denotes after
T3572 1376-1380 NN denotes days
T3571 1374-1375 CD denotes 4
T3570 1371-1373 TO denotes to
T3569 1368-1370 VB denotes SE
T3568 1365-1367 TO denotes to
T3567 1359-1364 RB denotes prior
T3566 1354-1358 NN denotes days
T3565 1352-1353 CD denotes 3
T3564 1347-1351 IN denotes from
T3563 1341-1346 NN denotes TNF-α
T3562 1338-1340 IN denotes of
T3561 1329-1337 NN denotes function
T3560 1325-1328 DT denotes the
T3559 1317-1324 VB denotes inhibit
T3558 1311-1316 JJ denotes least
T3557 1308-1310 IN denotes at
T3556 1298-1307 NN denotes schedules
T3555 1285-1297 JJ denotes experimental
T3554 1281-1284 PRP-DOLLAR- denotes our
T3553 1279-1280 -COMMA- denotes ,
T3552 1275-1279 RB denotes Thus
T3551 1268-1273 NN denotes point
T3550 1263-1267 NN denotes time
T3549 1258-1262 DT denotes this
T3548 1252-1257 VB denotes chose
T3547 1249-1251 PRP denotes we
T3546 1247-1248 -COMMA- denotes ,
T3545 1246-1247 -RRB- denotes ]
T3544 1240-1246 CD denotes 5-8,20
T3543 1239-1240 -LRB- denotes [
T3542 1231-1238 NN denotes studies
T3541 1222-1230 JJ denotes previous
T3540 1218-1221 PRP-DOLLAR- denotes our
T3539 1215-1217 IN denotes in
T3538 1212-1214 NN denotes SE
T3537 1206-1211 IN denotes after
T3536 1201-1205 NN denotes days
T3535 1197-1200 CD denotes 2-3
T3534 1194-1196 IN denotes at
T3533 1187-1193 VB denotes peaked
T3532 1181-1186 NN denotes edema
T3531 1171-1180 JJ denotes vasogenic
T3530 1168-1170 IN denotes of
T3529 1161-1167 NN denotes volume
T3528 1157-1160 DT denotes the
T3527 1151-1156 IN denotes Since
T3526 1142-1149 NN denotes surgery
T3525 1136-1141 IN denotes after
T3524 1128-1135 VB denotes infused
T3523 1116-1127 RB denotes immediately
T3522 1113-1115 VB denotes be
T3521 1110-1112 TO denotes to
T3520 1104-1109 VB denotes began
T3519 1094-1103 NN denotes compounds
T3518 1090-1093 DT denotes The
T3517 1082-1088 NN denotes animal
T3516 1077-1081 DT denotes each
T3515 1073-1076 IN denotes per
T3514 1066-1072 NN denotes μg/day
T3513 1062-1065 CD denotes 0.6
T3512 1058-1061 VB denotes was
T3511 1049-1057 NN denotes sTNFp55R
T3510 1046-1048 IN denotes of
T3509 1041-1045 NN denotes dose
T3508 1037-1040 DT denotes the
T3507 1035-1036 -COMMA- denotes ,
T3506 1026-1035 RB denotes Therefore
T3505 1020-1024 NN denotes week
T3504 1018-1019 CD denotes 1
T3503 1014-1017 IN denotes for
T3502 1005-1013 NN denotes compound
T3501 1002-1004 CC denotes or
T3500 994-1001 NN denotes vehicle
T3499 991-993 IN denotes of
T3498 985-990 NN denotes μl/hr
T3497 981-984 CD denotes 0.5
T3496 972-980 VB denotes received
T3495 964-971 NN denotes Animals
T3494 956-962 NN denotes region
T3493 949-955 JJ denotes dorsal
T3492 945-948 DT denotes the
T3491 942-944 IN denotes in
T3490 935-941 NN denotes pocket
T3489 922-934 JJ denotes subcutaneous
T3488 920-921 DT denotes a
T3487 917-919 IN denotes in
T3486 910-916 VB denotes placed
T3485 906-909 VB denotes was
T3484 901-905 NN denotes pump
T3483 897-900 DT denotes The
T3482 894-895 -RRB- denotes )
T3481 892-894 NNP denotes CA
T3480 890-891 -COMMA- denotes ,
T3479 881-890 NNP denotes Cupertino
T3478 879-880 -COMMA- denotes ,
T3477 874-879 NNP denotes Alzet
T3476 872-873 -COMMA- denotes ,
T3475 867-872 NN denotes 1007D
T3474 866-867 -LRB- denotes (
T3473 861-865 NN denotes pump
T3472 853-860 JJ denotes osmotic
T3471 850-852 DT denotes an
T3470 847-849 TO denotes to
T3469 837-846 VB denotes connected
T3468 833-836 CC denotes and
T3467 826-832 NN denotes cement
T3466 819-825 JJ denotes dental
T3465 814-818 IN denotes with
T3464 807-813 VB denotes sealed
T3463 803-806 VB denotes was
T3462 799-802 NN denotes kit
T3461 790-798 NN denotes infusion
T3460 786-789 DT denotes The
T3459 783-784 -RRB- denotes ]
T3458 781-783 CD denotes 24
T3457 780-781 -LRB- denotes [
T3456 773-779 NNP denotes Watson
T3455 769-772 CC denotes and
T3454 761-768 NNP denotes Paxinos
T3453 758-760 IN denotes of
T3452 752-757 NN denotes atlas
T3451 748-751 DT denotes the
T3450 745-747 TO denotes to
T3449 735-744 VB denotes according
T3448 733-734 -COMMA- denotes ,
T3349 224-234 VB denotes determined
T3348 220-223 VB denotes was
T3347 211-219 NN denotes sTNFp55R
T3346 208-210 IN denotes of
T3345 201-207 NN denotes dosage
T3344 197-200 DT denotes The
T3343 189-195 NN denotes groups
T3342 180-188 JJ denotes -treated
T3341 179-180 -RRB- denotes )
T3340 177-179 NN denotes MO
T3339 175-176 -COMMA- denotes ,
T3338 170-175 NNP denotes Louis
T3337 166-169 NNP denotes St.
T3336 164-165 -COMMA- denotes ,
T3335 161-164 NNP denotes Co.
T3334 147-160 NNP denotes Sigma-Aldrich
T3333 145-146 -COLON- denotes ;
T3332 140-145 NN denotes μg/ml
T3331 137-139 CD denotes 50
T3330 135-136 -COMMA- denotes ,
T3329 127-135 NN denotes sTNFp55R
T3328 126-127 -LRB- denotes (
T3327 117-125 NN denotes receptor
T3326 110-116 NN denotes TNFp55
T3325 102-109 JJ denotes soluble
T3324 98-101 CC denotes and
T3323 89-97 JJ denotes -treated
T3322 88-89 -RRB- denotes )
T3321 82-88 NN denotes saline
T3320 81-82 -LRB- denotes (
T3319 73-80 NN denotes vehicle
T3318 71-72 -COLON- denotes :
T3317 65-71 NN denotes groups
T3316 61-64 CD denotes two
T3315 56-60 IN denotes into
T3314 48-55 VB denotes divided
T3313 43-47 VB denotes were
T3312 38-42 NN denotes Rats
T3311 29-37 NN denotes infusion
T3310 24-28 NN denotes drug
T3309 0-23 JJ denotes Intracerebroventricular
T3447 732-733 -RRB- denotes )
T3446 723-732 NN denotes reference
T3445 720-722 IN denotes as
T3444 713-719 NN denotes bregma
T3443 708-712 IN denotes with
T3442 699-707 NN denotes position
T3441 693-698 NN denotes skull
T3440 688-692 JJ denotes flat
T3439 686-687 -COLON- denotes ;
T3438 681-686 NN denotes depth
T3437 678-680 NN denotes mm
T3436 674-677 CD denotes 3.5
T3435 672-673 -COLON- denotes -
T3434 670-671 -COLON- denotes ;
T3433 663-670 JJ denotes lateral
T3432 660-662 NN denotes mm
T3431 656-659 CD denotes 1.5
T3430 654-655 -COLON- denotes ;
T3429 645-654 JJ denotes posterior
T3428 642-644 NN denotes mm
T3427 640-641 CD denotes 1
T3426 639-640 -LRB- denotes (
T3425 629-638 NN denotes ventricle
T3424 621-628 JJ denotes lateral
T3423 615-620 JJ denotes right
T3422 611-614 DT denotes the
T3421 606-610 IN denotes into
T3420 604-605 -RRB- denotes )
T3419 602-604 NN denotes CA
T3418 600-601 -COMMA- denotes ,
T3417 591-600 NNP denotes Cupertino
T3416 589-590 -COMMA- denotes ,
T3415 584-589 NNP denotes Alzet
T3414 583-584 -LRB- denotes (
T3413 581-582 CD denotes 1
T3412 577-580 NN denotes kit
T3411 568-576 NN denotes infusion
T3410 562-567 NN denotes brain
T3409 560-561 DT denotes a
T3408 550-559 VB denotes introduce
T3407 547-549 TO denotes to
T3406 541-546 NN denotes skull
T3405 537-540 DT denotes the
T3404 529-536 IN denotes through
T3403 521-528 VB denotes drilled
T3402 516-520 VB denotes were
T3401 510-515 NN denotes holes
T3400 508-509 -COMMA- denotes ,
T3399 496-508 NN denotes implantation
T3398 491-495 NN denotes pump
T3397 483-490 JJ denotes osmotic
T3396 479-482 DT denotes the
T3395 475-478 IN denotes For
T3394 467-473 NN denotes frames
T3393 455-466 JJ denotes stereotaxic
T3392 453-454 DT denotes a
T3391 450-452 IN denotes in
T3390 443-449 VB denotes placed
T3389 439-442 CC denotes and
T3388 437-438 -RRB- denotes )
T3387 431-437 NNP denotes France
T3386 429-430 -COMMA- denotes ,
T3385 417-429 NNP denotes Laboratories
T3384 410-416 NNP denotes Virbac
T3383 408-409 -COLON- denotes ;
T3382 404-408 NN denotes i.m.
T3381 402-403 -COMMA- denotes ,
T3380 397-402 NN denotes mg/kg
T3379 394-396 CD denotes 50
T3378 392-393 -COMMA- denotes ,
T3377 384-392 NN denotes Zolretil
T3376 383-384 -LRB- denotes (
T3375 370-382 VB denotes anesthetized
T3374 365-369 VB denotes were
T3373 357-364 NN denotes Animals
T3372 350-355 NN denotes study
T3371 338-349 JJ denotes preliminary
T3370 334-337 DT denotes the
T3369 331-333 IN denotes in
T3368 321-330 NN denotes mortality
T3367 319-320 NN denotes %
T3366 318-319 CD denotes 5
T3365 313-317 IN denotes with
T3364 305-312 NN denotes animals
T3363 302-304 IN denotes of
T3362 300-301 NN denotes %
T3361 297-300 CD denotes 100
T3360 294-296 IN denotes in
T3359 285-293 NN denotes severity
T3358 274-284 JJ denotes comparable
T3357 271-273 IN denotes of
T3356 268-270 NN denotes SE
T3355 260-267 VB denotes induced
T3354 255-259 WDT denotes that
T3353 250-254 NN denotes dose
T3352 242-249 JJ denotes highest
T3351 238-241 DT denotes the
T3350 235-237 IN denotes as
R2454 T3311 T3309 arg1Of infusion,Intracerebroventricular
R2455 T3311 T3310 arg1Of infusion,drug
R2456 T3312 T3313 arg1Of Rats,were
R2457 T3312 T3314 arg2Of Rats,divided
R2458 T3314 T3313 arg2Of divided,were
R2459 T3314 T3315 arg1Of divided,into
R2460 T3314 T3343 arg1Of divided,groups
R2461 T3317 T3315 arg2Of groups,into
R2462 T3317 T3316 arg1Of groups,two
R2463 T3317 T3318 arg1Of groups,:
R2464 T3321 T3320 arg2Of saline,(
R2465 T3322 T3320 arg3Of ),(
R2466 T3323 T3324 arg1Of -treated,and
R2467 T3325 T3324 arg2Of soluble,and
R2468 T3327 T3318 arg2Of receptor,:
R2469 T3327 T3319 arg1Of receptor,vehicle
R2470 T3327 T3320 arg1Of receptor,(
R2471 T3327 T3323 arg1Of receptor,-treated
R2472 T3327 T3325 arg1Of receptor,soluble
R2473 T3327 T3326 arg1Of receptor,TNFp55
R2474 T3327 T3328 arg1Of receptor,(
R2475 T3329 T3328 arg2Of sTNFp55R,(
R2476 T3329 T3330 arg1Of sTNFp55R,","
R2477 T3329 T3333 arg1Of sTNFp55R,;
R2478 T3332 T3330 arg2Of μg/ml,","
R2479 T3332 T3331 arg1Of μg/ml,50
R2480 T3335 T3333 arg2Of Co.,;
R2481 T3335 T3334 arg1Of Co.,Sigma-Aldrich
R2482 T3335 T3336 arg1Of Co.,","
R2483 T3338 T3336 arg2Of Louis,","
R2484 T3338 T3337 arg1Of Louis,St.
R2485 T3338 T3339 arg1Of Louis,","
R2486 T3340 T3339 arg2Of MO,","
R2487 T3341 T3328 arg3Of ),(
R2488 T3343 T3342 arg1Of groups,-treated
R2489 T3345 T3344 arg1Of dosage,The
R2490 T3345 T3346 arg1Of dosage,of
R2491 T3345 T3348 arg1Of dosage,was
R2492 T3345 T3349 arg2Of dosage,determined
R2493 T3347 T3346 arg2Of sTNFp55R,of
R2494 T3349 T3348 arg2Of determined,was
R2495 T3349 T3350 arg1Of determined,as
R2496 T3353 T3350 arg2Of dose,as
R2497 T3353 T3351 arg1Of dose,the
R2498 T3353 T3352 arg1Of dose,highest
R2499 T3353 T3354 arg1Of dose,that
R2500 T3353 T3355 arg1Of dose,induced
R2501 T3356 T3355 arg2Of SE,induced
R2502 T3356 T3357 arg1Of SE,of
R2503 T3359 T3357 arg2Of severity,of
R2504 T3359 T3358 arg1Of severity,comparable
R2505 T3359 T3360 arg1Of severity,in
R2506 T3362 T3360 arg2Of %,in
R2507 T3362 T3361 arg1Of %,100
R2508 T3362 T3363 arg1Of %,of
R2509 T3362 T3365 arg1Of %,with
R2510 T3364 T3363 arg2Of animals,of
R2511 T3366 T3367 arg1Of 5,%
R2512 T3368 T3365 arg2Of mortality,with
R2513 T3368 T3366 arg1Of mortality,5
R2514 T3368 T3369 arg1Of mortality,in
R2515 T3372 T3369 arg2Of study,in
R2516 T3372 T3370 arg1Of study,the
R2517 T3372 T3371 arg1Of study,preliminary
R2518 T3373 T3374 arg1Of Animals,were
R2519 T3373 T3375 arg2Of Animals,anesthetized
R2520 T3373 T3390 arg2Of Animals,placed
R2521 T3375 T3376 arg1Of anesthetized,(
R2522 T3375 T3389 arg1Of anesthetized,and
R2523 T3377 T3378 arg1Of Zolretil,","
R2524 T3377 T3381 arg1Of Zolretil,","
R2525 T3377 T3383 arg1Of Zolretil,;
R2526 T3380 T3378 arg2Of mg/kg,","
R2527 T3380 T3379 arg1Of mg/kg,50
R2528 T3382 T3381 arg2Of i.m.,","
R2529 T3383 T3376 arg2Of ;,(
R2530 T3385 T3383 arg2Of Laboratories,;
R2531 T3385 T3384 arg1Of Laboratories,Virbac
R2532 T3385 T3386 arg1Of Laboratories,","
R2533 T3387 T3386 arg2Of France,","
R2534 T3388 T3376 arg3Of ),(
R2535 T3389 T3374 arg2Of and,were
R2536 T3390 T3389 arg2Of placed,and
R2537 T3390 T3391 arg1Of placed,in
R2538 T3394 T3391 arg2Of frames,in
R2539 T3394 T3392 arg1Of frames,a
R2540 T3394 T3393 arg1Of frames,stereotaxic
R2541 T3399 T3395 arg2Of implantation,For
R2542 T3399 T3396 arg1Of implantation,the
R2543 T3399 T3397 arg1Of implantation,osmotic
R2544 T3399 T3398 arg1Of implantation,pump
R2545 T3401 T3402 arg1Of holes,were
R2546 T3401 T3403 arg2Of holes,drilled
R2547 T3403 T3395 arg1Of drilled,For
R2548 T3403 T3400 arg1Of drilled,","
R2549 T3403 T3402 arg2Of drilled,were
R2550 T3403 T3404 arg1Of drilled,through
R2551 T3403 T3414 arg1Of drilled,(
R2552 T3403 T3421 arg1Of drilled,into
R2553 T3403 T3448 arg1Of drilled,","
R2554 T3403 T3449 arg1Of drilled,according
R2555 T3406 T3404 arg2Of skull,through
R2556 T3406 T3405 arg1Of skull,the
R2557 T3406 T3407 modOf skull,to
R2558 T3408 T3407 arg1Of introduce,to
R2559 T3412 T3408 arg2Of kit,introduce
R2560 T3412 T3409 arg1Of kit,a
R2561 T3412 T3410 arg1Of kit,brain
R2562 T3412 T3411 arg1Of kit,infusion
R2563 T3412 T3413 arg1Of kit,1
R2564 T3415 T3416 arg1Of Alzet,","
R2565 T3416 T3414 arg2Of ",",(
R2566 T3416 T3418 arg1Of ",",","
R2567 T3417 T3416 arg2Of Cupertino,","
R2568 T3419 T3418 arg2Of CA,","
R2569 T3420 T3414 arg3Of ),(
R2570 T3425 T3421 arg2Of ventricle,into
R2571 T3425 T3422 arg1Of ventricle,the
R2572 T3425 T3423 arg1Of ventricle,right
R2573 T3425 T3424 arg1Of ventricle,lateral
R2574 T3425 T3426 arg1Of ventricle,(
R2575 T3428 T3427 arg1Of mm,1
R2576 T3428 T3429 arg1Of mm,posterior
R2577 T3428 T3430 arg1Of mm,;
R2578 T3430 T3426 arg2Of ;,(
R2579 T3430 T3439 arg1Of ;,;
R2580 T3431 T3432 arg1Of 1.5,mm
R2581 T3432 T3433 arg1Of mm,lateral
R2582 T3432 T3436 arg1Of mm,3.5
R2583 T3433 T3434 arg1Of lateral,;
R2584 T3433 T3435 arg1Of lateral,-
R2585 T3436 T3435 arg2Of 3.5,-
R2586 T3436 T3437 arg1Of 3.5,mm
R2587 T3438 T3430 arg2Of depth,;
R2588 T3438 T3431 arg1Of depth,1.5
R2589 T3442 T3439 arg2Of position,;
R2590 T3442 T3440 arg1Of position,flat
R2591 T3442 T3441 arg1Of position,skull
R2592 T3442 T3443 arg1Of position,with
R2593 T3442 T3445 arg1Of position,as
R2594 T3444 T3443 arg2Of bregma,with
R2595 T3446 T3445 arg2Of reference,as
R2596 T3447 T3426 arg3Of ),(
R2597 T3450 T3449 arg2Of to,according
R2598 T3452 T3450 arg2Of atlas,to
R2599 T3452 T3451 arg1Of atlas,the
R2600 T3452 T3453 arg1Of atlas,of
R2601 T3454 T3455 arg1Of Paxinos,and
R2602 T3455 T3453 arg2Of and,of
R2603 T3456 T3455 arg2Of Watson,and
R2604 T3456 T3457 arg1Of Watson,[
R2605 T3458 T3457 arg2Of 24,[
R2606 T3459 T3457 arg3Of ],[
R2607 T3462 T3460 arg1Of kit,The
R2608 T3462 T3461 arg1Of kit,infusion
R2609 T3462 T3463 arg1Of kit,was
R2610 T3462 T3464 arg2Of kit,sealed
R2611 T3462 T3469 arg2Of kit,connected
R2612 T3464 T3465 arg1Of sealed,with
R2613 T3464 T3468 arg1Of sealed,and
R2614 T3467 T3465 arg2Of cement,with
R2615 T3467 T3466 arg1Of cement,dental
R2616 T3468 T3463 arg2Of and,was
R2617 T3469 T3468 arg2Of connected,and
R2618 T3469 T3470 arg1Of connected,to
R2619 T3473 T3470 arg2Of pump,to
R2620 T3473 T3471 arg1Of pump,an
R2621 T3473 T3472 arg1Of pump,osmotic
R2622 T3473 T3474 arg1Of pump,(
R2623 T3475 T3474 arg2Of 1007D,(
R2624 T3475 T3476 arg1Of 1007D,","
R2625 T3475 T3480 arg1Of 1007D,","
R2626 T3477 T3476 arg2Of Alzet,","
R2627 T3477 T3478 arg1Of Alzet,","
R2628 T3479 T3478 arg2Of Cupertino,","
R2629 T3481 T3480 arg2Of CA,","
R2630 T3482 T3474 arg3Of ),(
R2631 T3484 T3483 arg1Of pump,The
R2632 T3484 T3485 arg1Of pump,was
R2633 T3484 T3486 arg2Of pump,placed
R2634 T3486 T3485 arg2Of placed,was
R2635 T3486 T3487 arg1Of placed,in
R2636 T3490 T3487 arg2Of pocket,in
R2637 T3490 T3488 arg1Of pocket,a
R2638 T3490 T3489 arg1Of pocket,subcutaneous
R2639 T3490 T3491 arg1Of pocket,in
R2640 T3494 T3491 arg2Of region,in
R2641 T3494 T3492 arg1Of region,the
R2642 T3494 T3493 arg1Of region,dorsal
R2643 T3495 T3496 arg1Of Animals,received
R2644 T3496 T3503 arg1Of received,for
R2645 T3498 T3496 arg2Of μl/hr,received
R2646 T3498 T3497 arg1Of μl/hr,0.5
R2647 T3498 T3499 arg1Of μl/hr,of
R2648 T3500 T3501 arg1Of vehicle,or
R2649 T3501 T3499 arg2Of or,of
R2650 T3502 T3501 arg2Of compound,or
R2651 T3505 T3503 arg2Of week,for
R2652 T3505 T3504 arg1Of week,1
R2653 T3509 T3508 arg1Of dose,the
R2654 T3509 T3510 arg1Of dose,of
R2655 T3509 T3512 arg1Of dose,was
R2656 T3511 T3510 arg2Of sTNFp55R,of
R2657 T3512 T3506 arg1Of was,Therefore
R2658 T3512 T3507 arg1Of was,","
R2659 T3514 T3512 arg2Of μg/day,was
R2660 T3514 T3513 arg1Of μg/day,0.6
R2661 T3514 T3515 arg1Of μg/day,per
R2662 T3517 T3515 arg2Of animal,per
R2663 T3517 T3516 arg1Of animal,each
R2664 T3519 T3518 arg1Of compounds,The
R2665 T3519 T3520 arg1Of compounds,began
R2666 T3519 T3522 arg1Of compounds,be
R2667 T3519 T3524 arg2Of compounds,infused
R2668 T3524 T3520 arg2Of infused,began
R2669 T3524 T3521 arg1Of infused,to
R2670 T3524 T3522 arg2Of infused,be
R2671 T3524 T3523 arg1Of infused,immediately
R2672 T3524 T3525 arg1Of infused,after
R2673 T3526 T3525 arg2Of surgery,after
R2674 T3529 T3528 arg1Of volume,the
R2675 T3529 T3530 arg1Of volume,of
R2676 T3529 T3533 arg1Of volume,peaked
R2677 T3532 T3530 arg2Of edema,of
R2678 T3532 T3531 arg1Of edema,vasogenic
R2679 T3533 T3527 arg2Of peaked,Since
R2680 T3533 T3534 arg1Of peaked,at
R2681 T3533 T3537 arg1Of peaked,after
R2682 T3536 T3534 arg2Of days,at
R2683 T3536 T3535 arg1Of days,2-3
R2684 T3538 T3537 arg2Of SE,after
R2685 T3538 T3539 arg1Of SE,in
R2686 T3542 T3539 arg2Of studies,in
R2687 T3542 T3540 arg1Of studies,our
R2688 T3542 T3541 arg1Of studies,previous
R2689 T3542 T3543 arg1Of studies,[
R2690 T3544 T3543 arg2Of "5-8,20",[
R2691 T3545 T3543 arg3Of ],[
R2692 T3547 T3548 arg1Of we,chose
R2693 T3548 T3527 arg1Of chose,Since
R2694 T3548 T3546 arg1Of chose,","
R2695 T3551 T3548 arg2Of point,chose
R2696 T3551 T3549 arg1Of point,this
R2697 T3551 T3550 arg1Of point,time
R2698 T3556 T3554 arg1Of schedules,our
R2699 T3556 T3555 arg1Of schedules,experimental
R2700 T3556 T3559 arg1Of schedules,inhibit
R2701 T3556 T3569 arg1Of schedules,SE
R2702 T3558 T3557 arg1Of least,at
R2703 T3559 T3552 arg1Of inhibit,Thus
R2704 T3559 T3553 arg1Of inhibit,","
R2705 T3559 T3558 arg1Of inhibit,least
R2706 T3559 T3567 arg1Of inhibit,prior
R2707 T3559 T3568 modOf inhibit,to
R2708 T3561 T3559 arg2Of function,inhibit
R2709 T3561 T3560 arg1Of function,the
R2710 T3561 T3562 arg1Of function,of
R2711 T3561 T3564 arg1Of function,from
R2712 T3563 T3562 arg2Of TNF-α,of
R2713 T3566 T3564 arg2Of days,from
R2714 T3566 T3565 arg1Of days,3
R2715 T3569 T3568 arg1Of SE,to
R2716 T3569 T3570 arg1Of SE,to
R2717 T3569 T3573 arg1Of SE,after
R2718 T3569 T3575 arg1Of SE,when
R2719 T3571 T3570 arg2Of 4,to
R2720 T3573 T3572 arg1Of after,days
R2721 T3574 T3573 arg2Of SE,after
R2722 T3577 T3576 arg1Of volume,the
R2723 T3577 T3578 arg1Of volume,of
R2724 T3577 T3581 arg1Of volume,peaked
R2725 T3580 T3578 arg2Of edema,of
R2726 T3580 T3579 arg1Of edema,vasogenic
R2727 T3581 T3575 arg2Of peaked,when

bionlp-st-ge-2016-test-proteins

Id Subject Object Predicate Lexical cue
T3298 1341-1346 Protein denotes TNF-α
T3297 1050-1057 Protein denotes TNFp55R
T3296 212-219 Protein denotes TNFp55R
T3295 128-135 Protein denotes TNFp55R
T3294 110-125 Protein denotes TNFp55 receptor

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T3582 1341-1346 http://www.uniprot.org/uniprot/P01375 denotes TNF-α

UBERON-AE

Id Subject Object Predicate Lexical cue
T3275 713-719 http://purl.obolibrary.org/obo/UBERON_0013406 denotes bregma
T3274 615-638 http://purl.obolibrary.org/obo/UBERON_0013162 denotes right lateral ventricle
T3273 562-567 http://purl.obolibrary.org/obo/UBERON_0000955 denotes brain
T3272 693-698 http://purl.obolibrary.org/obo/UBERON_0003129 denotes skull
T3271 541-546 http://purl.obolibrary.org/obo/UBERON_0003129 denotes skull

GO-BP

Id Subject Object Predicate Lexical cue
T3301 645-654 http://purl.obolibrary.org/obo/GO_0022001 denotes posterior
T3300 892-894 http://purl.obolibrary.org/obo/GO_0033968 denotes CA
T3299 602-604 http://purl.obolibrary.org/obo/GO_0033968 denotes CA

GO-MF

Id Subject Object Predicate Lexical cue
T3303 892-894 http://purl.obolibrary.org/obo/GO_0033968 denotes CA
T3302 602-604 http://purl.obolibrary.org/obo/GO_0033968 denotes CA

sentences

Id Subject Object Predicate Lexical cue
T3287 1275-1432 Sentence denotes Thus, our experimental schedules at least inhibit the function of TNF-α from 3 days prior to SE to 4 days after SE when the volume of vasogenic edema peaked.
T3286 1151-1274 Sentence denotes Since the volume of vasogenic edema peaked at 2-3 days after SE in our previous studies [5-8,20], we chose this time point.
T3285 1090-1150 Sentence denotes The compounds began to be immediately infused after surgery.
T3284 1026-1089 Sentence denotes Therefore, the dose of sTNFp55R was 0.6 μg/day per each animal.
T3283 964-1025 Sentence denotes Animals received 0.5 μl/hr of vehicle or compound for 1 week.
T3282 897-963 Sentence denotes The pump was placed in a subcutaneous pocket in the dorsal region.
T3281 786-896 Sentence denotes The infusion kit was sealed with dental cement and connected to an osmotic pump (1007D, Alzet, Cupertino, CA).
T3280 475-785 Sentence denotes For the osmotic pump implantation, holes were drilled through the skull to introduce a brain infusion kit 1 (Alzet, Cupertino, CA) into the right lateral ventricle (1 mm posterior; 1.5 mm lateral; - 3.5 mm depth; flat skull position with bregma as reference), according to the atlas of Paxinos and Watson [24].
T3279 357-474 Sentence denotes Animals were anesthetized (Zolretil, 50 mg/kg, i.m.; Virbac Laboratories, France) and placed in a stereotaxic frames.
T3278 197-356 Sentence denotes The dosage of sTNFp55R was determined as the highest dose that induced SE of comparable severity in 100% of animals with 5% mortality in the preliminary study.
T3277 38-196 Sentence denotes Rats were divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor (sTNFp55R, 50 μg/ml; Sigma-Aldrich Co., St. Louis, MO)-treated groups.
T3276 0-37 Sentence denotes Intracerebroventricular drug infusion
T54 0-37 Sentence denotes Intracerebroventricular drug infusion
T55 38-196 Sentence denotes Rats were divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor (sTNFp55R, 50 μg/ml; Sigma-Aldrich Co., St. Louis, MO)-treated groups.
T56 197-356 Sentence denotes The dosage of sTNFp55R was determined as the highest dose that induced SE of comparable severity in 100% of animals with 5% mortality in the preliminary study.
T57 357-474 Sentence denotes Animals were anesthetized (Zolretil, 50 mg/kg, i.m.; Virbac Laboratories, France) and placed in a stereotaxic frames.
T58 475-785 Sentence denotes For the osmotic pump implantation, holes were drilled through the skull to introduce a brain infusion kit 1 (Alzet, Cupertino, CA) into the right lateral ventricle (1 mm posterior; 1.5 mm lateral; - 3.5 mm depth; flat skull position with bregma as reference), according to the atlas of Paxinos and Watson [24].
T59 786-896 Sentence denotes The infusion kit was sealed with dental cement and connected to an osmotic pump (1007D, Alzet, Cupertino, CA).
T60 897-963 Sentence denotes The pump was placed in a subcutaneous pocket in the dorsal region.
T61 964-1025 Sentence denotes Animals received 0.5 μl/hr of vehicle or compound for 1 week.
T62 1026-1089 Sentence denotes Therefore, the dose of sTNFp55R was 0.6 μg/day per each animal.
T63 1090-1150 Sentence denotes The compounds began to be immediately infused after surgery.
T64 1151-1274 Sentence denotes Since the volume of vasogenic edema peaked at 2-3 days after SE in our previous studies [5-8,20], we chose this time point.
T65 1275-1432 Sentence denotes Thus, our experimental schedules at least inhibit the function of TNF-α from 3 days prior to SE to 4 days after SE when the volume of vasogenic edema peaked.

simple1

Id Subject Object Predicate Lexical cue
T3308 1341-1346 Protein denotes TNF-α
T3307 1050-1057 Protein denotes TNFp55R
T3306 212-219 Protein denotes TNFp55R
T3305 128-135 Protein denotes TNFp55R
T3304 110-125 Protein denotes TNFp55 receptor

BioNLP16_DUT

Id Subject Object Predicate Lexical cue
T3916 1317-1324 Negative_regulation denotes inhibit
T3915 1341-1346 Protein denotes TNF-α
T3914 1050-1057 Protein denotes TNFp55R
T3913 212-219 Protein denotes TNFp55R
T3912 128-135 Protein denotes TNFp55R
T3911 110-125 Protein denotes TNFp55 receptor
R3026 T3915 T3916 themeOf TNF-α,inhibit

BioNLP16_Messiy

Id Subject Object Predicate Lexical cue
T3881 1317-1324 Negative_regulation denotes inhibit
T3880 1341-1346 Protein denotes TNF-α
T3879 1050-1057 Protein denotes TNFp55R
T3878 212-219 Protein denotes TNFp55R
T3877 128-135 Protein denotes TNFp55R
T3876 110-125 Protein denotes TNFp55 receptor
R3021 T3880 T3881 themeOf TNF-α,inhibit

DLUT931

Id Subject Object Predicate Lexical cue
T3887 1317-1324 Negative_regulation denotes inhibit
T3886 1341-1346 Protein denotes TNF-α
T3885 1050-1057 Protein denotes TNFp55R
T3884 212-219 Protein denotes TNFp55R
T3883 128-135 Protein denotes TNFp55R
T3882 110-125 Protein denotes TNFp55 receptor
R3022 T3886 T3887 themeOf TNF-α,inhibit

bionlp-st-ge-2016-test-ihmc

Id Subject Object Predicate Lexical cue
T3923 1374-1431 Entity denotes 4 days after SE when the volume of vasogenic edema peaked
T3922 268-355 Protein denotes SE of comparable severity in 100% of animals with 5% mortality in the preliminary study
T3921 128-131 Protein denotes TNF
T3920 147-179 Protein denotes Sigma-Aldrich Co., St. Louis, MO
T3919 197-214 Protein denotes The dosage of sTN
T3918 1352-1370 Protein denotes 3 days prior to SE
T3917 48-125 Protein denotes divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor
T3934 48-125 Regulation denotes divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor
T3933 1050-1053 Protein denotes TNF
T3932 560-582 Entity denotes a brain infusion kit 1
T3931 1338-1346 Protein denotes of TNF-α
T3930 82-88 Entity denotes saline
T3929 1212-1214 Entity denotes SE
T3928 699-732 Entity denotes position with bregma as reference
T3927 0-37 Entity denotes Intracerebroventricular drug infusion
T3926 786-802 Entity denotes The infusion kit
T3925 1037-1057 Entity denotes the dose of sTNFp55R
T3924 0-37 Entity denotes Intracerebroventricular drug infusion
R3027 T3917 T3934 themeOf divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor,divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T3875 1431-1432 . denotes .
T3874 1425-1431 VBD denotes peaked
T3873 1419-1424 NN denotes edema
T3872 1409-1418 JJ denotes vasogenic
T3871 1406-1408 IN denotes of
T3870 1399-1405 NN denotes volume
T3869 1395-1398 DT denotes the
T3868 1390-1394 WRB denotes when
T3867 1387-1389 NNP denotes SE
T3866 1381-1386 IN denotes after
T3865 1376-1380 NNS denotes days
T3864 1374-1375 CD denotes 4
T3863 1371-1373 TO denotes to
T3862 1368-1370 VB denotes SE
T3861 1365-1367 TO denotes to
T3860 1359-1364 RB denotes prior
T3859 1354-1358 NNS denotes days
T3858 1352-1353 CD denotes 3
T3857 1347-1351 IN denotes from
T3856 1341-1346 NN denotes TNF-α
T3855 1338-1340 IN denotes of
T3854 1329-1337 NN denotes function
T3853 1325-1328 DT denotes the
T3852 1317-1324 VB denotes inhibit
T3851 1311-1316 JJS denotes least
T3850 1308-1310 IN denotes at
T3849 1298-1307 NNS denotes schedules
T3848 1285-1297 JJ denotes experimental
T3847 1281-1284 PRP$ denotes our
T3846 1279-1280 , denotes ,
T3845 1275-1279 RB denotes Thus
T3844 1273-1274 . denotes .
T3843 1268-1273 NN denotes point
T3842 1263-1267 NN denotes time
T3841 1258-1262 DT denotes this
T3840 1252-1257 VBD denotes chose
T3839 1249-1251 PRP denotes we
T3838 1247-1248 , denotes ,
T3837 1246-1247 NNP denotes ]
T3836 1243-1246 CD denotes ,20
T3835 1240-1243 CD denotes 5-8
T3834 1239-1240 NNP denotes [
T3833 1231-1238 NNS denotes studies
T3832 1222-1230 JJ denotes previous
T3831 1218-1221 PRP$ denotes our
T3830 1215-1217 IN denotes in
T3829 1212-1214 NNP denotes SE
T3828 1206-1211 IN denotes after
T3827 1201-1205 NNS denotes days
T3826 1197-1200 CD denotes 2-3
T3825 1194-1196 IN denotes at
T3824 1187-1193 VBD denotes peaked
T3823 1181-1186 NN denotes edema
T3822 1171-1180 JJ denotes vasogenic
T3821 1168-1170 IN denotes of
T3820 1161-1167 NN denotes volume
T3819 1157-1160 DT denotes the
T3818 1151-1156 IN denotes Since
T3817 1149-1150 . denotes .
T3816 1142-1149 NN denotes surgery
T3815 1136-1141 IN denotes after
T3814 1128-1135 VBN denotes infused
T3813 1116-1127 RB denotes immediately
T3812 1113-1115 VB denotes be
T3811 1110-1112 TO denotes to
T3810 1104-1109 VBD denotes began
T3809 1094-1103 NNS denotes compounds
T3808 1090-1093 DT denotes The
T3807 1088-1089 . denotes .
T3806 1082-1088 NN denotes animal
T3805 1077-1081 DT denotes each
T3804 1073-1076 IN denotes per
T3803 1069-1072 NN denotes day
T3802 1068-1069 NN denotes /
T3801 1066-1068 NN denotes μg
T3800 1062-1065 CD denotes 0.6
T3799 1058-1061 VBD denotes was
T3798 1049-1057 NN denotes sTNFp55R
T3797 1046-1048 IN denotes of
T3796 1041-1045 NN denotes dose
T3795 1037-1040 DT denotes the
T3794 1035-1036 , denotes ,
T3793 1026-1035 RB denotes Therefore
T3792 1024-1025 . denotes .
T3791 1020-1024 NN denotes week
T3790 1018-1019 CD denotes 1
T3789 1014-1017 IN denotes for
T3788 1005-1013 NN denotes compound
T3787 1002-1004 CC denotes or
T3786 994-1001 NN denotes vehicle
T3785 991-993 IN denotes of
T3784 988-990 NN denotes hr
T3783 987-988 NN denotes /
T3782 985-987 NN denotes μl
T3781 981-984 CD denotes 0.5
T3780 972-980 VBD denotes received
T3779 964-971 NNS denotes Animals
T3778 962-963 . denotes .
T3777 956-962 NN denotes region
T3776 949-955 JJ denotes dorsal
T3775 945-948 DT denotes the
T3774 942-944 IN denotes in
T3773 935-941 NN denotes pocket
T3772 922-934 JJ denotes subcutaneous
T3771 920-921 DT denotes a
T3770 917-919 IN denotes in
T3769 910-916 VBN denotes placed
T3768 906-909 VBD denotes was
T3767 901-905 NN denotes pump
T3766 897-900 DT denotes The
T3765 895-896 . denotes .
T3764 894-895 -RRB- denotes )
T3763 892-894 NNP denotes CA
T3762 890-891 , denotes ,
T3761 881-890 NNP denotes Cupertino
T3760 879-880 , denotes ,
T3759 874-879 NNP denotes Alzet
T3758 872-873 , denotes ,
T3757 867-872 NNP denotes 1007D
T3756 866-867 -LRB- denotes (
T3755 861-865 NN denotes pump
T3754 853-860 JJ denotes osmotic
T3753 850-852 DT denotes an
T3752 847-849 TO denotes to
T3751 837-846 VBN denotes connected
T3750 833-836 CC denotes and
T3749 826-832 NN denotes cement
T3748 819-825 JJ denotes dental
T3747 814-818 IN denotes with
T3746 807-813 VBN denotes sealed
T3745 803-806 VBD denotes was
T3744 799-802 NN denotes kit
T3743 790-798 NN denotes infusion
T3742 786-789 DT denotes The
T3741 784-785 . denotes .
T3740 783-784 NNP denotes ]
T3739 781-783 CD denotes 24
T3738 780-781 NNP denotes [
T3737 773-779 NNP denotes Watson
T3736 769-772 CC denotes and
T3735 761-768 NNP denotes Paxinos
T3734 758-760 IN denotes of
T3733 752-757 NNS denotes atlas
T3732 748-751 DT denotes the
T3731 745-747 TO denotes to
T3730 735-744 VBG denotes according
T3729 733-734 , denotes ,
T3728 732-733 -RRB- denotes )
T3727 723-732 NN denotes reference
T3726 720-722 IN denotes as
T3725 713-719 NN denotes bregma
T3724 708-712 IN denotes with
T3723 699-707 NN denotes position
T3722 693-698 NN denotes skull
T3721 688-692 JJ denotes flat
T3720 686-687 : denotes ;
T3719 681-686 NN denotes depth
T3718 678-680 NN denotes mm
T3717 674-677 CD denotes 3.5
T3716 672-673 : denotes -
T3715 670-671 : denotes ;
T3714 663-670 NN denotes lateral
T3713 660-662 NN denotes mm
T3712 656-659 CD denotes 1.5
T3711 654-655 : denotes ;
T3710 645-654 NN denotes posterior
T3709 642-644 NN denotes mm
T3708 640-641 CD denotes 1
T3663 408-409 : denotes ;
T3662 404-408 NN denotes i.m.
T3661 402-403 , denotes ,
T3660 397-402 NN denotes mg/kg
T3659 394-396 CD denotes 50
T3658 392-393 , denotes ,
T3657 384-392 NNP denotes Zolretil
T3656 383-384 -LRB- denotes (
T3655 370-382 JJ denotes anesthetized
T3654 365-369 VBD denotes were
T3653 357-364 NNS denotes Animals
T3652 355-356 . denotes .
T3651 350-355 NN denotes study
T3650 338-349 JJ denotes preliminary
T3649 334-337 DT denotes the
T3648 331-333 IN denotes in
T3647 321-330 NN denotes mortality
T3646 319-320 NN denotes %
T3645 318-319 CD denotes 5
T3644 313-317 IN denotes with
T3643 305-312 NNS denotes animals
T3642 302-304 IN denotes of
T3641 300-301 NN denotes %
T3640 297-300 CD denotes 100
T3639 294-296 IN denotes in
T3638 285-293 NN denotes severity
T3637 274-284 JJ denotes comparable
T3636 271-273 IN denotes of
T3635 268-270 NNP denotes SE
T3634 260-267 VBD denotes induced
T3633 255-259 WDT denotes that
T3632 250-254 NN denotes dose
T3631 242-249 JJS denotes highest
T3630 238-241 DT denotes the
T3629 235-237 IN denotes as
T3628 224-234 VBN denotes determined
T3627 220-223 VBD denotes was
T3626 211-219 NN denotes sTNFp55R
T3625 208-210 IN denotes of
T3624 201-207 NN denotes dosage
T3623 197-200 DT denotes The
T3622 195-196 . denotes .
T3621 189-195 NNS denotes groups
T3620 181-188 VBN denotes treated
T3619 180-181 : denotes -
T3618 179-180 -RRB- denotes )
T3617 177-179 NNP denotes MO
T3616 175-176 , denotes ,
T3615 170-175 NNP denotes Louis
T3614 166-169 NNP denotes St.
T3613 164-165 , denotes ,
T3612 161-164 NNP denotes Co.
T3611 147-160 NNP denotes Sigma-Aldrich
T3610 145-146 : denotes ;
T3609 143-145 NN denotes ml
T3608 142-143 NN denotes /
T3607 140-142 NN denotes μg
T3606 137-139 CD denotes 50
T3605 135-136 , denotes ,
T3604 127-135 JJ denotes sTNFp55R
T3603 126-127 -LRB- denotes (
T3602 117-125 NN denotes receptor
T3601 110-116 NN denotes TNFp55
T3600 102-109 JJ denotes soluble
T3599 98-101 CC denotes and
T3598 90-97 VBN denotes treated
T3597 89-90 : denotes -
T3596 88-89 -RRB- denotes )
T3595 82-88 NN denotes saline
T3594 81-82 -LRB- denotes (
T3593 73-80 NN denotes vehicle
T3592 71-72 : denotes :
T3591 65-71 NNS denotes groups
T3590 61-64 CD denotes two
T3589 56-60 IN denotes into
T3588 48-55 VBN denotes divided
T3587 43-47 VBD denotes were
T3586 38-42 NNS denotes Rats
T3585 29-37 NN denotes infusion
T3584 24-28 NN denotes drug
T3583 0-23 JJ denotes Intracerebroventricular
T3707 639-640 -LRB- denotes (
T3706 629-638 NN denotes ventricle
T3705 621-628 JJ denotes lateral
T3704 615-620 JJ denotes right
T3703 611-614 DT denotes the
T3702 606-610 IN denotes into
T3701 604-605 -RRB- denotes )
T3700 602-604 NNP denotes CA
T3699 600-601 , denotes ,
T3698 591-600 NNP denotes Cupertino
T3697 589-590 , denotes ,
T3696 584-589 NNP denotes Alzet
T3695 583-584 -LRB- denotes (
T3694 581-582 CD denotes 1
T3693 577-580 NN denotes kit
T3692 568-576 NN denotes infusion
T3691 562-567 NN denotes brain
T3690 560-561 DT denotes a
T3689 550-559 VB denotes introduce
T3688 547-549 TO denotes to
T3687 541-546 NN denotes skull
T3686 537-540 DT denotes the
T3685 529-536 IN denotes through
T3684 521-528 VBN denotes drilled
T3683 516-520 VBD denotes were
T3682 510-515 NNS denotes holes
T3681 508-509 , denotes ,
T3680 496-508 NN denotes implantation
T3679 491-495 NN denotes pump
T3678 483-490 JJ denotes osmotic
T3677 479-482 DT denotes the
T3676 475-478 IN denotes For
T3675 473-474 . denotes .
T3674 467-473 NNS denotes frames
T3673 455-466 JJ denotes stereotaxic
T3672 453-454 DT denotes a
T3671 450-452 IN denotes in
T3670 443-449 VBN denotes placed
T3669 439-442 CC denotes and
T3668 437-438 -RRB- denotes )
T3667 431-437 NNP denotes France
T3666 429-430 , denotes ,
T3665 417-429 NNPS denotes Laboratories
T3664 410-416 NNP denotes Virbac
R2728 T3583 T3585 amod Intracerebroventricular,infusion
R2729 T3584 T3585 compound drug,infusion
R2730 T3585 T3586 compound infusion,Rats
R2731 T3586 T3588 nsubjpass Rats,divided
R2732 T3587 T3588 auxpass were,divided
R2733 T3588 T3588 ROOT divided,divided
R2734 T3589 T3588 prep into,divided
R2735 T3590 T3591 nummod two,groups
R2736 T3591 T3589 pobj groups,into
R2737 T3592 T3591 punct :,groups
R2738 T3593 T3591 appos vehicle,groups
R2739 T3594 T3595 punct (,saline
R2740 T3595 T3593 appos saline,vehicle
R2741 T3596 T3593 punct ),vehicle
R2742 T3597 T3593 punct -,vehicle
R2743 T3598 T3593 acl treated,vehicle
R2744 T3599 T3598 cc and,treated
R2745 T3600 T3598 conj soluble,treated
R2746 T3601 T3602 compound TNFp55,receptor
R2747 T3602 T3620 ccomp receptor,treated
R2748 T3603 T3609 punct (,ml
R2749 T3604 T3609 amod sTNFp55R,ml
R2750 T3605 T3609 punct ",",ml
R2751 T3606 T3607 nummod 50,μg
R2752 T3607 T3609 nmod μg,ml
R2753 T3608 T3609 compound /,ml
R2754 T3609 T3602 appos ml,receptor
R2755 T3610 T3620 punct ;,treated
R2756 T3611 T3612 compound Sigma-Aldrich,Co.
R2757 T3612 T3620 nsubj Co.,treated
R2758 T3613 T3612 punct ",",Co.
R2759 T3614 T3615 compound St.,Louis
R2760 T3615 T3612 npadvmod Louis,Co.
R2761 T3616 T3612 punct ",",Co.
R2762 T3617 T3612 appos MO,Co.
R2763 T3618 T3617 punct ),MO
R2764 T3619 T3620 punct -,treated
R2765 T3620 T3621 amod treated,groups
R2766 T3621 T3591 appos groups,groups
R2767 T3622 T3588 punct .,divided
R2768 T3623 T3624 det The,dosage
R2769 T3624 T3628 nsubjpass dosage,determined
R2770 T3625 T3624 prep of,dosage
R2771 T3626 T3625 pobj sTNFp55R,of
R2772 T3627 T3628 auxpass was,determined
R2773 T3628 T3628 ROOT determined,determined
R2774 T3629 T3628 prep as,determined
R2775 T3630 T3632 det the,dose
R2776 T3631 T3632 amod highest,dose
R2777 T3632 T3629 pobj dose,as
R2778 T3633 T3634 nsubj that,induced
R2779 T3634 T3632 relcl induced,dose
R2780 T3635 T3634 dobj SE,induced
R2781 T3636 T3635 prep of,SE
R2782 T3637 T3638 amod comparable,severity
R2783 T3638 T3636 pobj severity,of
R2784 T3639 T3634 prep in,induced
R2785 T3640 T3641 nummod 100,%
R2786 T3641 T3639 pobj %,in
R2787 T3642 T3641 prep of,%
R2788 T3643 T3642 pobj animals,of
R2789 T3644 T3634 prep with,induced
R2790 T3645 T3646 nummod 5,%
R2791 T3646 T3647 compound %,mortality
R2792 T3647 T3644 pobj mortality,with
R2793 T3648 T3647 prep in,mortality
R2794 T3649 T3651 det the,study
R2795 T3650 T3651 amod preliminary,study
R2871 T3726 T3689 prep as,introduce
R2872 T3727 T3726 pobj reference,as
R2873 T3728 T3689 punct ),introduce
R2874 T3729 T3684 punct ",",drilled
R2875 T3730 T3684 prep according,drilled
R2876 T3731 T3730 prep to,according
R2877 T3732 T3733 det the,atlas
R2878 T3733 T3731 pobj atlas,to
R2879 T3734 T3733 prep of,atlas
R2880 T3735 T3734 pobj Paxinos,of
R2881 T3736 T3735 cc and,Paxinos
R2882 T3737 T3738 compound Watson,[
R2883 T3738 T3735 conj [,Paxinos
R2884 T3739 T3740 nummod 24,]
R2885 T3740 T3735 conj ],Paxinos
R2886 T3741 T3684 punct .,drilled
R2887 T3742 T3744 det The,kit
R2888 T3743 T3744 compound infusion,kit
R2889 T3744 T3746 nsubjpass kit,sealed
R2890 T3745 T3746 auxpass was,sealed
R2891 T3746 T3746 ROOT sealed,sealed
R2892 T3747 T3746 prep with,sealed
R2893 T3748 T3749 amod dental,cement
R2894 T3749 T3747 pobj cement,with
R2895 T3750 T3749 cc and,cement
R2896 T3751 T3746 conj connected,sealed
R2897 T3752 T3751 prep to,connected
R2898 T3753 T3755 det an,pump
R2899 T3754 T3755 amod osmotic,pump
R2900 T3755 T3752 pobj pump,to
R2901 T3756 T3755 punct (,pump
R2902 T3757 T3757 ROOT 1007D,1007D
R2903 T3758 T3757 punct ",",1007D
R2904 T3759 T3757 conj Alzet,1007D
R2905 T3760 T3759 punct ",",Alzet
R2906 T3761 T3759 conj Cupertino,Alzet
R2907 T3762 T3761 punct ",",Cupertino
R2908 T3763 T3761 conj CA,Cupertino
R2909 T3764 T3757 punct ),1007D
R2910 T3765 T3746 punct .,sealed
R2911 T3766 T3767 det The,pump
R2912 T3767 T3769 nsubjpass pump,placed
R2913 T3768 T3769 auxpass was,placed
R2914 T3769 T3769 ROOT placed,placed
R2915 T3770 T3769 prep in,placed
R2916 T3771 T3773 det a,pocket
R2917 T3772 T3773 amod subcutaneous,pocket
R2918 T3773 T3770 pobj pocket,in
R2919 T3774 T3773 prep in,pocket
R2920 T3775 T3777 det the,region
R2921 T3776 T3777 amod dorsal,region
R2922 T3777 T3774 pobj region,in
R2923 T3778 T3769 punct .,placed
R2924 T3779 T3780 nsubj Animals,received
R2925 T3780 T3780 ROOT received,received
R2926 T3781 T3782 nummod 0.5,μl
R2927 T3782 T3784 compound μl,hr
R2928 T3783 T3784 compound /,hr
R2929 T3784 T3780 dobj hr,received
R2930 T3785 T3784 prep of,hr
R2931 T3786 T3785 pobj vehicle,of
R2932 T3787 T3786 cc or,vehicle
R2933 T3788 T3786 conj compound,vehicle
R2934 T3789 T3780 prep for,received
R2935 T3790 T3791 nummod 1,week
R2936 T3791 T3789 pobj week,for
R2937 T3792 T3780 punct .,received
R2938 T3793 T3799 advmod Therefore,was
R2939 T3794 T3799 punct ",",was
R2940 T3795 T3796 det the,dose
R2941 T3796 T3799 nsubj dose,was
R2942 T3797 T3796 prep of,dose
R2943 T3798 T3797 pobj sTNFp55R,of
R2944 T3799 T3799 ROOT was,was
R2945 T3800 T3801 nummod 0.6,μg
R2946 T3801 T3803 amod μg,day
R2947 T3802 T3803 compound /,day
R2948 T3803 T3799 attr day,was
R2949 T3804 T3803 prep per,day
R2950 T3805 T3806 det each,animal
R2951 T3806 T3804 pobj animal,per
R2952 T3807 T3799 punct .,was
R2953 T3808 T3809 det The,compounds
R2954 T3809 T3810 nsubj compounds,began
R2796 T3651 T3648 pobj study,in
R2797 T3652 T3628 punct .,determined
R2798 T3653 T3654 nsubj Animals,were
R2799 T3654 T3665 ccomp were,Laboratories
R2800 T3655 T3654 acomp anesthetized,were
R2801 T3656 T3657 punct (,Zolretil
R2802 T3657 T3665 ccomp Zolretil,Laboratories
R2803 T3658 T3657 punct ",",Zolretil
R2804 T3659 T3660 nummod 50,mg/kg
R2805 T3660 T3657 appos mg/kg,Zolretil
R2806 T3661 T3662 punct ",",i.m.
R2807 T3662 T3657 conj i.m.,Zolretil
R2808 T3663 T3665 punct ;,Laboratories
R2809 T3664 T3665 compound Virbac,Laboratories
R2810 T3665 T3665 ROOT Laboratories,Laboratories
R2811 T3666 T3665 punct ",",Laboratories
R2812 T3667 T3665 conj France,Laboratories
R2813 T3668 T3667 punct ),France
R2814 T3669 T3665 cc and,Laboratories
R2815 T3670 T3665 conj placed,Laboratories
R2816 T3671 T3670 prep in,placed
R2817 T3672 T3674 det a,frames
R2818 T3673 T3674 amod stereotaxic,frames
R2819 T3674 T3671 pobj frames,in
R2820 T3675 T3665 punct .,Laboratories
R2821 T3676 T3684 prep For,drilled
R2822 T3677 T3680 det the,implantation
R2823 T3678 T3680 amod osmotic,implantation
R2824 T3679 T3680 compound pump,implantation
R2825 T3680 T3676 pobj implantation,For
R2826 T3681 T3684 punct ",",drilled
R2827 T3682 T3684 nsubjpass holes,drilled
R2828 T3683 T3684 auxpass were,drilled
R2829 T3684 T3684 ROOT drilled,drilled
R2830 T3685 T3684 prep through,drilled
R2831 T3686 T3687 det the,skull
R2832 T3687 T3685 pobj skull,through
R2833 T3688 T3689 aux to,introduce
R2834 T3689 T3684 advcl introduce,drilled
R2835 T3690 T3693 det a,kit
R2836 T3691 T3692 compound brain,infusion
R2837 T3692 T3693 compound infusion,kit
R2838 T3693 T3689 dobj kit,introduce
R2839 T3694 T3693 nummod 1,kit
R2840 T3695 T3693 punct (,kit
R2841 T3696 T3693 appos Alzet,kit
R2842 T3697 T3696 punct ",",Alzet
R2843 T3698 T3696 conj Cupertino,Alzet
R2844 T3699 T3698 punct ",",Cupertino
R2845 T3700 T3698 conj CA,Cupertino
R2846 T3701 T3693 punct ),kit
R2847 T3702 T3689 prep into,introduce
R2848 T3703 T3706 det the,ventricle
R2849 T3704 T3706 amod right,ventricle
R2850 T3705 T3706 amod lateral,ventricle
R2851 T3706 T3702 pobj ventricle,into
R2852 T3707 T3710 punct (,posterior
R2853 T3708 T3709 nummod 1,mm
R2854 T3709 T3710 compound mm,posterior
R2855 T3710 T3723 compound posterior,position
R2856 T3711 T3710 punct ;,posterior
R2857 T3712 T3713 nummod 1.5,mm
R2858 T3713 T3714 compound mm,lateral
R2859 T3714 T3710 appos lateral,posterior
R2860 T3715 T3710 punct ;,posterior
R2861 T3716 T3710 punct -,posterior
R2862 T3717 T3718 nummod 3.5,mm
R2863 T3718 T3719 compound mm,depth
R2864 T3719 T3710 appos depth,posterior
R2865 T3720 T3710 punct ;,posterior
R2866 T3721 T3722 amod flat,skull
R2867 T3722 T3723 compound skull,position
R2868 T3723 T3689 dobj position,introduce
R2869 T3724 T3689 prep with,introduce
R2870 T3725 T3724 pobj bregma,with
R2955 T3810 T3810 ROOT began,began
R2956 T3811 T3814 aux to,infused
R2957 T3812 T3814 auxpass be,infused
R2958 T3813 T3814 advmod immediately,infused
R2959 T3814 T3810 xcomp infused,began
R2960 T3815 T3814 prep after,infused
R2961 T3816 T3815 pobj surgery,after
R2962 T3817 T3810 punct .,began
R2963 T3818 T3824 mark Since,peaked
R2964 T3819 T3820 det the,volume
R2965 T3820 T3824 nsubj volume,peaked
R2966 T3821 T3820 prep of,volume
R2967 T3822 T3823 amod vasogenic,edema
R2968 T3823 T3821 pobj edema,of
R2969 T3824 T3840 advcl peaked,chose
R2970 T3825 T3824 prep at,peaked
R2971 T3826 T3827 nummod 2-3,days
R2972 T3827 T3825 pobj days,at
R2973 T3828 T3840 prep after,chose
R2974 T3829 T3837 nmod SE,]
R2975 T3830 T3829 prep in,SE
R2976 T3831 T3833 poss our,studies
R2977 T3832 T3833 amod previous,studies
R2978 T3833 T3830 pobj studies,in
R2979 T3834 T3837 nmod [,]
R2980 T3835 T3834 nummod 5-8,[
R2981 T3836 T3837 compound ",20",]
R2982 T3837 T3828 pobj ],after
R2983 T3838 T3840 punct ",",chose
R2984 T3839 T3840 nsubj we,chose
R2985 T3840 T3840 ROOT chose,chose
R2986 T3841 T3843 det this,point
R2987 T3842 T3843 compound time,point
R2988 T3843 T3840 dobj point,chose
R2989 T3844 T3840 punct .,chose
R2990 T3845 T3852 advmod Thus,inhibit
R2991 T3846 T3852 punct ",",inhibit
R2992 T3847 T3849 poss our,schedules
R2993 T3848 T3849 amod experimental,schedules
R2994 T3849 T3852 nsubj schedules,inhibit
R2995 T3850 T3851 advmod at,least
R2996 T3851 T3852 advmod least,inhibit
R2997 T3852 T3852 ROOT inhibit,inhibit
R2998 T3853 T3854 det the,function
R2999 T3854 T3852 dobj function,inhibit
R3000 T3855 T3854 prep of,function
R3001 T3856 T3855 pobj TNF-α,of
R3002 T3857 T3852 prep from,inhibit
R3003 T3858 T3859 nummod 3,days
R3004 T3859 T3857 pobj days,from
R3005 T3860 T3852 advmod prior,inhibit
R3006 T3861 T3860 prep to,prior
R3007 T3862 T3861 pobj SE,to
R3008 T3863 T3862 prep to,SE
R3009 T3864 T3865 nummod 4,days
R3010 T3865 T3863 pobj days,to
R3011 T3866 T3852 prep after,inhibit
R3012 T3867 T3866 pobj SE,after
R3013 T3868 T3874 advmod when,peaked
R3014 T3869 T3870 det the,volume
R3015 T3870 T3874 nsubj volume,peaked
R3016 T3871 T3870 prep of,volume
R3017 T3872 T3873 amod vasogenic,edema
R3018 T3873 T3871 pobj edema,of
R3019 T3874 T3852 advcl peaked,inhibit
R3020 T3875 T3852 punct .,inhibit

bionlp-st-ge-2016-test-tees

Id Subject Object Predicate Lexical cue
T3890 211-219 Protein denotes sTNFp55R
T3889 127-135 Protein denotes sTNFp55R
T3888 110-125 Protein denotes TNFp55 receptor
T3893 1317-1324 Negative_regulation denotes inhibit
T3892 1341-1346 Protein denotes TNF-α
T3891 1049-1057 Protein denotes sTNFp55R
R3023 T3892 T3893 themeOf TNF-α,inhibit

testone

Id Subject Object Predicate Lexical cue
T3259 1317-1324 Negative_regulation denotes inhibit
T3258 1341-1346 Protein denotes TNF-α
T3257 1050-1057 Protein denotes TNFp55R
T3256 212-219 Protein denotes TNFp55R
T3255 128-135 Protein denotes TNFp55R
T3254 110-125 Protein denotes TNFp55 receptor

test3

Id Subject Object Predicate Lexical cue
T3270 1341-1346 Protein denotes TNF-α
T3269 1317-1324 Negative_regulation denotes inhibit
T3268 1049-1057 Protein denotes sTNFp55R
T3267 211-219 Protein denotes sTNFp55R
T3266 127-135 Protein denotes sTNFp55R
T3265 110-125 Protein denotes TNFp55 receptor
T3264 1341-1346 Protein denotes TNF-α
T3263 1050-1057 Protein denotes TNFp55R
T3262 212-219 Protein denotes TNFp55R
T3261 128-135 Protein denotes TNFp55R
T3260 110-125 Protein denotes TNFp55 receptor
R2450 T3266 T3265 equivalentTo sTNFp55R,TNFp55 receptor
R2451 T3270 T3269 themeOf TNF-α,inhibit